The Reagent Resource Support for AIDS Vaccine Development Program provides for procurement or production of reagents essential to AIDS vaccine development and evaluation, plus the independent performance of quality assurance testing of these reagents.
This program provides reagents, resources, and quality assurance/quality control analysis (QA/QC) in support of the DAIDS vaccine research effort including the procurement or production and distribution of working quantities of common reagents needed for immunological evaluation of the vaccinated subjects participating in DAIDS-supported clinical and preclinical trials. For example, acquiring agents required for the HIV Vaccine Trials Network (HVTN). These may include viral gene products and associated peptides, adjuvants, cytokines, virus stocks, expression vectors, monoclonal and polyclonal antibodies, and sometimes unforeseen but appropriately and timely produced reagents. These reagents are generated for evaluating vaccine safety, immunogenicity, and efficacy. In some cases, such reagents may not be commercially available and would require customized production and quality control. The independent QA/QC testing performed on the reagents supplied through this contract aims to establish standardization of assays among the laboratories supported by this contract, thus improving the reproducibility and comparability of results among DAIDS-supported vaccine research groups.
Dr. Jon Warren
Division of AIDS, Preclinical Research and Development Branch
Last Updated June 27, 2006